Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Section...
October 13 2017 - 9:37AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report
on the Symposium which was held on Fexapotide Triflutate studies at
the Annual Meeting of the American Urological Association,
Northeast Section in Savannah, October 12 at 4 pm. The abstract
from the presentation is available at info@nymox.com.
The symposium, “Fexapotide Triflutate: A Safe
and Effective First In Class Injectable for BPH” was chaired by
James Bailen MD FACS of Louisville, KY. The other panel members at
the Symposium were Dr. Franklin D. Gaylis of San Diego CA, Dr.
Stephen Richardson of Salt Lake City UT, and Dr. Jed Kaminetsky of
New York NY.
Dr. Bailen said, "FT is a simple administration for any
urologist, and offers a major improvement in BPH management with
minimal side effects and great safety profile."
Dr. Kaminetsky stated “Fexapotide is an exciting
treatment alternative for the symptomatic man suffering from lower
urinary tract symptoms without the commonly seen side effects
associated with approved medicines and minimally invasive
procedures. If approved it will fill a medical need and offer the
practising urologist a safe and effective new treatment to help
their patients.”
At the Symposium detailed clinical data on the
Phase 3 clinical trials that have been completed for Fexapotide and
that have shown excellent safety and efficacy for the treatment of
BPH was presented. Scientific data supporting the safety and
efficacy from non-clinical and laboratory testing and analysis was
demonstrated. The main presentation was followed by a panel
discussion and by an interactive question and answer session with
the specialist doctors in attendance.
Dr. Richardson added further, "Because of the safety profile and
the great long-term efficacy, Fexapotide could potentially become a
first-line treatment for countless men with BPH."
Fexapotide has been filed for approval in Europe
and the filing was accepted for review in September 2017. Nymox's
lead drug Fexapotide has been in development for over 10 years and
has been tested by expert clinical trial investigative teams in
over 70 distinguished clinical trial centers throughout the US, and
has been found after 7 years of prospective placebo controlled
double blind studies of treatment of 995 U.S. men with prostate
enlargement to not only show clinically meaningful and durable
relief of BPH symptoms, but also to show a major reduction in the
incidence of prostate cancer, compared to placebo and compared to
the known and expected normal incidence of the disease. The same
clinical program has also shown in a long-term blinded placebo
crossover group study an 82-95% reduction in the number of these
patients who required surgery after they received crossover
Fexapotide in the trial, as compared to patients who did not
receive Fexapotide but instead received crossover conventional
approved BPH treatments (p<.0001).
For more information please
contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2016, and its Quarterly Reports.
For Further Information
Contact:Paul AverbackNymox Pharmaceutical
Corporation1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2024 to May 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From May 2023 to May 2024